Dietmar W Siemann

Dietmar W Siemann,

Professor; Associate Director For Education And Training, UFHCC

Department: MD-RADIATION ONCOLOGY
Business Phone: (352) 265-0287
Business Email: siemadw@ufl.edu

Teaching Profile

Courses Taught
2016-2025
GMS6934 Cancer Biology Data Discussion
2017-2018,2020-2023
GMS5905 Special Topics in Biomedical Sciences
2006-2009,2012-2025
GMS6065 Fundamentals of Cancer Biology
2014,2017-2019,2019-2022,2021-2023
GMS6053 Cancer Biology and Therapeutics
2018
GMS7979 Advanced Research
2018
GMS7980 Research for Doctoral Dissertation
2018
PHC7980 Research for Doctoral Dissertation
2015-2017
GMS6895 CTS Journal Club
2013-2017
GMS6003 Fundamentals of Graduate Research and Professional Development
2015
GMS6692 Research Conference in Anatomy and Cell Biology
2015
GMS6683 Fundamentals of Vascular Physiology and Pathology

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-5190-5761

Publications

2023
Biophysics in tumor growth and progression: from single mechano-sensitive molecules to mechanomedicine.
Oncogene. 42(47):3457-3490 [DOI] 10.1038/s41388-023-02844-x. [PMID] 37864030.
2023
Functional Interrogation of Ca2+ Signals in Human Cancer Cells In Vitro and Ex Vivo by Fluorescent Microscopy and Molecular Tools.
Methods in molecular biology (Clifton, N.J.). 2679:95-125 [DOI] 10.1007/978-1-0716-3271-0_7. [PMID] 37300611.
2023
Realizations of vascularized tissues: From in vitro platforms to in vivo grafts
Biophysics Reviews. 4(1) [DOI] 10.1063/5.0131972. [PMID] 36938117.
2022
Automatic Multi-functional Integration Program (AMFIP) towards all-optical mechano-electrophysiology interrogation.
PloS one. 17(7) [DOI] 10.1371/journal.pone.0266098. [PMID] 35901062.
2022
FGF7 peptide (FGF7p) mimetic mitigates bladder urothelial injury from cyclophosphamide.
Physiological reports. 10(7) [DOI] 10.14814/phy2.15241. [PMID] 35388988.
2022
Human cancer cells generate spontaneous calcium transients and intercellular waves that modulate tumor growth.
Biomaterials. 290 [DOI] 10.1016/j.biomaterials.2022.121823. [PMID] 36209577.
2022
Towards an integrative understanding of cancer mechanobiology: calcium, YAP, and microRNA under biophysical forces.
Soft matter. 18(6):1112-1148 [DOI] 10.1039/d1sm01618k. [PMID] 35089300.
2021
All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System.
Journal of visualized experiments : JoVE. (178) [DOI] 10.3791/62934. [PMID] 34978284.
2021
Bioprinting on Live Tissue for Investigating Cancer Cell Dynamics.
Tissue engineering. Part A. 27(7-8):438-453 [DOI] 10.1089/ten.TEA.2020.0190. [PMID] 33059528.
2021
Inhibition of the Axl pathway impairs breast and prostate cancer metastasis to the bones and bone remodeling.
Clinical & experimental metastasis. 38(3):321-335 [DOI] 10.1007/s10585-021-10093-z. [PMID] 33791875.
2021
Normal tissue and tumor microenvironment adaptations to aerobic exercise enhance doxorubicin anti-tumor efficacy and ameliorate its cardiotoxicity in retired breeder mice.
Oncotarget. 12(18):1737-1748 [DOI] 10.18632/oncotarget.28057. [PMID] 34504647.
2021
Therapeutic Modification of Hypoxia.
Clinical oncology (Royal College of Radiologists (Great Britain)). 33(11):e492-e509 [DOI] 10.1016/j.clon.2021.08.014. [PMID] 34535359.
2021
Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.
International journal of molecular sciences. 22(18) [DOI] 10.3390/ijms22189953. [PMID] 34576116.
2021
Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices.
Journal of bone oncology. 28 [DOI] 10.1016/j.jbo.2021.100357. [PMID] 33912384.
2020
Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment.
Cancers. 12(7) [DOI] 10.3390/cancers12071850. [PMID] 32660000.
2019
Axl signaling is an important mediator of tumor angiogenesis.
Oncotarget. 10(30):2887-2898 [DOI] 10.18632/oncotarget.26882. [PMID] 31080559.
2019
c-Src is required for hypoxia-induced metastasis-associated functions in prostate cancer cells.
OncoTargets and therapy. 12:3519-3529 [DOI] 10.2147/OTT.S201320. [PMID] 31190858.
2019
Cathepsin L secretion by host and neoplastic cells potentiates invasion.
Oncotarget. 10(53):5560-5568 [DOI] 10.18632/oncotarget.27182. [PMID] 31565189.
2019
Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion.
Oncotarget. 10(2):184-197 [DOI] 10.18632/oncotarget.26546. [PMID] 30719213.
2019
Prostate cancer cell growth characteristics in serum and prostate-conditioned media from moderate-intensity exercise-trained healthy and tumor-bearing rats.
American journal of cancer research. 9(4):650-667 [PMID] 31105994.
2019
Reliability of blood lactate as a measure of exercise intensity in different strains of mice during forced treadmill running.
PloS one. 14(5) [DOI] 10.1371/journal.pone.0215584. [PMID] 31050686.
2019
Tumor oxygenation and cancer therapy-then and now.
The British journal of radiology. 92(1093) [DOI] 10.1259/bjr.20170955. [PMID] 29513032.
2018
Exercise and the Tumor Microenvironment: Potential Therapeutic Implications.
Exercise and sport sciences reviews. 46(1):56-64 [DOI] 10.1249/JES.0000000000000137. [PMID] 29166299.
2018
Have Clinical Trials Properly Assessed c-Met Inhibitors?
Trends in cancer. 4(2):94-97 [DOI] 10.1016/j.trecan.2017.11.009. [PMID] 29458966.
2018
Stability and Mobility of Magnetic Nanoparticles in Biological Environments Determined from Dynamic Magnetic Susceptibility Measurements.
Bioconjugate chemistry. 29(8):2793-2805 [DOI] 10.1021/acs.bioconjchem.8b00419. [PMID] 30011185.
2018
Stromal cells in breast cancer as a potential therapeutic target.
Oncotarget. 9(34):23761-23779 [DOI] 10.18632/oncotarget.25245. [PMID] 29805773.
2018
Treatment with Src inhibitor Dasatinib results in elevated metastatic potential in the 4T1 murine mammary carcinoma model.
Tumor & microenvironment. 1(1):30-36 [DOI] 10.4103/tme.tme_19_17. [PMID] 29658958.
2017
Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.
Cancer investigation. 35(8):519-534 [DOI] 10.1080/07357907.2017.1364745. [PMID] 28872367.
2016
Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94.
Clinical & experimental metastasis. 33(5):461-73 [DOI] 10.1007/s10585-016-9790-1. [PMID] 27055649.
2016
Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.
International journal of cancer. 138(11):2665-77 [DOI] 10.1002/ijc.29992. [PMID] 26757413.
2016
Chemosensitizing AML cells by targeting bone marrow endothelial cells.
Experimental hematology. 44(5):363-377.e5 [DOI] 10.1016/j.exphem.2016.02.003. [PMID] 26898708.
2016
Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells.
The Journal of clinical investigation. 126(11):4174-4186 [DOI] 10.1172/JCI86623. [PMID] 27721239.
2016
Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation.
American journal of cancer research. 6(5):1078-88 [PMID] 27294000.
2016
Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.
Cancer letters. 380(2):525-533 [DOI] 10.1016/j.canlet.2014.09.035. [PMID] 25312939.
2015
Cathepsin L targeting in cancer treatment.
Pharmacology & therapeutics. 155:105-16 [DOI] 10.1016/j.pharmthera.2015.08.007. [PMID] 26299995.
2015
Histone Methyltransferase hSETD1A Is a Novel Regulator of Metastasis in Breast Cancer.
Molecular cancer research : MCR. 13(3):461-9 [DOI] 10.1158/1541-7786.MCR-14-0389. [PMID] 25373480.
2015
Modulation of the tumor vasculature and oxygenation to improve therapy.
Pharmacology & therapeutics. 153:107-24 [DOI] 10.1016/j.pharmthera.2015.06.006. [PMID] 26073310.
2015
Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.
Bioorganic & medicinal chemistry. 23(21):6974-92 [DOI] 10.1016/j.bmc.2015.09.036. [PMID] 26462052.
2015
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Cancer letters. 360(1):60-7 [DOI] 10.1016/j.canlet.2015.02.005. [PMID] 25676691.
2014
Activation of a Subset of Growth Factor-Associated Genes in Cetuximab-Sensitive Colorectal Cancer Geo Cells With Kras Mutation
Cancer Research. 74(19, S):5507-5507 [DOI] 10.1158/1538-7445.AM2014-5507.
2014
Assessment of Anti-Tumor Activity of the Cathepsin L Inhibitor, Kgp94
Cancer Research. 74(19, S):1816-1816 [DOI] 10.1158/1538-7445.AM2014-1816.
2014
Combining Tyrosine Kinase Inhibitors and Isoflavones To Target Metastatic Activity in Prostate Cancer Cells
Cancer Research. 74(19, S):4037-4037 [DOI] 10.1158/1538-7445.AM2014-4037.
2014
Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model.
Anti-cancer drugs. 25(3):332-9 [DOI] 10.1097/CAD.0000000000000061. [PMID] 24304691.
2014
In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors.
Biomedical optics express. 5(6):1965-79 [DOI] 10.1364/BOE.5.001965. [PMID] 24940553.
2014
In-Vivo Evaluation of the Anti-Metastatic Efficacy of Small Molecule Cathepsin L Inhibitor Kgp94 in a Prostate Cancer Model
Cancer Research. 74(19, S):4030-4030 [DOI] 10.1158/1538-7445.AM2014-4030.
2014
Limitations of the dorsal skinfold window chamber model in evaluating anti-angiogenic therapy during early phase of angiogenesis.
Vascular cell. 6 [DOI] 10.1186/2045-824X-6-17. [PMID] 25101168.
2014
Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise.
Journal of the National Cancer Institute. 106(4) [DOI] 10.1093/jnci/dju036. [PMID] 24627275.
2014
MRI-based computational model of heterogeneous tracer transport following local infusion into a mouse hind limb tumor.
PloS one. 9(3) [DOI] 10.1371/journal.pone.0089594. [PMID] 24619021.
2013
Adenomatous polyposis coli-mediated accumulation of abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation of normal breast epithelial cells.
Neoplasia (New York, N.Y.). 15(4):454-60 [PMID] 23555190.
2013
Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells.
Clinical & experimental metastasis. 30(7):891-902 [DOI] 10.1007/s10585-013-9590-9. [PMID] 23748470.
2013
Cell-based selection provides novel molecular probes for cancer stem cells.
International journal of cancer. 132(11):2578-88 [DOI] 10.1002/ijc.27936. [PMID] 23150432.
2013
Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice.
American journal of veterinary research. 74(5):771-8 [DOI] 10.2460/ajvr.74.5.771. [PMID] 23627391.
2013
Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model.
Journal of applied physiology (Bethesda, Md. : 1985). 115(12):1846-54 [DOI] 10.1152/japplphysiol.00949.2013. [PMID] 24177690.
2013
Role of Vascular Dysfunction in Prostate Tumor Perfusion During Exercise
The FASEB's Journal. 27
2013
Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo.
Blood. 121(4):707-15 [DOI] 10.1182/blood-2012-05-433045. [PMID] 23212515.
2012
Acute Exercise Increases Prostate Tumor Blood Flow in Rats
The FASEB's Journal. 26
2012
Another road leads to HIF-1 activation: implications for prostate cancer progression.
Asian journal of andrology. 14(2):241-2 [DOI] 10.1038/aja.2011.163. [PMID] 22101943.
2012
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
BMC cancer. 12 [DOI] 10.1186/1471-2407-12-198. [PMID] 22639908.
2012
Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells.
Gene therapy. 19(4):375-84 [DOI] 10.1038/gt.2011.105. [PMID] 21776025.
2012
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation.
Clinical & experimental metastasis. 29(3):253-61 [DOI] 10.1007/s10585-011-9447-z. [PMID] 22286523.
2012
Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Clinical & experimental metastasis. 29(2):133-42 [DOI] 10.1007/s10585-011-9436-2. [PMID] 22130962.
2012
Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617.
Microvascular research. 83(3):290-7 [DOI] 10.1016/j.mvr.2012.02.008. [PMID] 22387475.
2012
Src-signaling interference impairs the dissemination of blood-borne tumor cells.
Cell and tissue research. 349(2):541-50 [DOI] 10.1007/s00441-012-1415-7. [PMID] 22526632.
2012
Vascular development in mouse lung metastases.
American journal of cancer research. 2(5):581-8 [PMID] 22957309.
2011
E-cadherin plasticity in prostate cancer stem cell invasion.
American journal of cancer research. 1(1):71-84 [PMID] 21968440.
2011
Impact of hypoxia on the metastatic potential of human prostate cancer cells.
International journal of radiation oncology, biology, physics. 81(2):521-8 [DOI] 10.1016/j.ijrobp.2011.04.027. [PMID] 21640519.
2011
Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation.
Proceedings of the National Academy of Sciences of the United States of America. 108(37):15231-6 [DOI] 10.1073/pnas.1104662108. [PMID] 21896759.
2011
Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.
Microvascular research. 81(1):44-51 [DOI] 10.1016/j.mvr.2010.10.003. [PMID] 20974154.
2011
The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.
Cancer treatment reviews. 37(1):63-74 [DOI] 10.1016/j.ctrv.2010.05.001. [PMID] 20570444.
2011
Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.
International journal of radiation biology. 87(11):1126-34 [DOI] 10.3109/09553002.2011.605418. [PMID] 21815749.
2010
BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Molecular cancer therapeutics. 9(6):1554-61 [DOI] 10.1158/1535-7163.MCT-10-0359. [PMID] 20515943.
2010
Cell proliferation index determination by immunohistochemical detection of hCDC47 protein.
Applied immunohistochemistry & molecular morphology : AIMM. 18(3):278-82 [DOI] 10.1097/PAI.0b013e3181c6c949. [PMID] 20048674.
2010
E-Cadherin Plasticity in Tumor-Initiating Stem-Like Cells Regulates Prostate Cancer Cell Invasion
Ejc Supplements. 8(7) [DOI] 10.1016/S1359-6349(10)72177-7.
2010
Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells.
The Journal of urology. 183(5):2045-53 [DOI] 10.1016/j.juro.2009.12.092. [PMID] 20303530.
2010
Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.
Anticancer research. 30(11):4405-13 [PMID] 21115886.
2010
In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503.
Oncology reports. 23(3):685-92 [PMID] 20127007.
2010
Leukemia regression by vascular disruption and antiangiogenic therapy.
Blood. 116(9):1539-47 [DOI] 10.1182/blood-2009-06-230474. [PMID] 20472832.
2010
Temporal aspects of the action of ASA404 (vadimezan; DMXAA).
Expert opinion on investigational drugs. 19(11):1413-25 [DOI] 10.1517/13543784.2010.529128. [PMID] 20964495.
2009
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
Expert opinion on investigational drugs. 18(2):189-97 [DOI] 10.1517/13543780802691068. [PMID] 19236265.
2009
Aml Regression By Vascular Disruption With Oxi4503 and Anti-Angiogenesis With Bevacizumab.
Blood. 114
2009
Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger.
Blood. 114(19):4310-9 [DOI] 10.1182/blood-2009-03-211342. [PMID] 19717647.
2009
Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapy.
American journal of veterinary research. 70(1):127-33 [DOI] 10.2460/ajvr.70.1.127. [PMID] 19119958.
2009
Impact of Tumor Cell Vegf Expression On the in Vivo Efficacy of Vandetanib (Zactima (Tm); Zd6474)
Anticancer Research. 29:1987-1992
2009
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
Anticancer research. 29(6):1987-92 [PMID] 19528456.
2009
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
International journal of radiation oncology, biology, physics. 73(3):897-903 [DOI] 10.1016/j.ijrobp.2008.10.031. [PMID] 19215823.
2009
Vascular targeted therapies in oncology.
Cell and tissue research. 335(1):241-8 [DOI] 10.1007/s00441-008-0646-0. [PMID] 18752004.
2009
X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas.
Translational oncology. 2(1):31-8 [PMID] 19252749.
2008
Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
Anticancer research. 28(4B):2027-31 [PMID] 18751370.
2008
Intrinsic radiosensitivity and repair of sublethal radiation-induced damage in canine osteosarcoma cell lines.
American journal of veterinary research. 69(9):1197-202 [DOI] 10.2460/ajvr.69.9.1197. [PMID] 18764694.
2008
Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.
Journal of immunology (Baltimore, Md. : 1950). 181(1):346-53 [PMID] 18566400.
2008
Targeting Metastatic Tumor Cell Functions By Inhibition of New Blood Vessel Formation With the Selective Vegf Signal Inhibitor, Cediranib (Recentin (Tm), Azd2171) Or Src Signaling Interference Using the Small Molecule Src Inhibitor, Azd0530
Ejc Supplements. 6(12):180-181 [DOI] 10.1016/S1359-6349(08)72509-6.
2007
An update on the clinical development of drugs to disable tumor vasculature.
Expert opinion on drug discovery. 2(10):1357-67 [DOI] 10.1517/17460441.2.10.1357. [PMID] 23484531.
2007
Characterizing the tumor response to treatment with combretastatin A4 phosphate.
International journal of radiation oncology, biology, physics. 68(1):211-7 [PMID] 17448875.
2007
Monitoring the treatment efficacy of the vascular disrupting agent CA4P.
European journal of cancer (Oxford, England : 1990). 43(10):1622-9 [PMID] 17451938.
2006
Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment.
Anticancer research. 26(5A):3445-53 [PMID] 17094465.
2006
Current development status of small-molecule vascular disrupting agents.
Current opinion in investigational drugs (London, England : 2000). 7(6):522-8 [PMID] 16784022.
2006
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(13):4090-4 [PMID] 16818709.
2006
Evaluations of the renal cell carcinoma model Caki-1 using a silicon based microvascular casting technique.
Technology in cancer research & treatment. 5(1):45-51 [PMID] 16417401.
2006
Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique.
European journal of cancer (Oxford, England : 1990). 42(17):3073-8 [PMID] 16956760.
2006
Impact of VEGF expression on the physiological characteristics of clonal cell lines.
In vivo (Athens, Greece). 20(6B):815-21 [PMID] 17203773.
2006
Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
Cancer research. 66(24):11520-39 [PMID] 17178843.
2006
Recombinant adeno-associated and adenoviral vectors for the transduction of pancreatic and colon carcinoma.
Anticancer research. 26(1A):311-7 [PMID] 16475712.
2006
VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.
International journal of radiation oncology, biology, physics. 65(3):836-41 [PMID] 16751064.
2005
Differentiation and definition of vascular-targeted therapies.
Clinical cancer research : an official journal of the American Association for Cancer Research. 11(2 Pt 1):416-20 [PMID] 15701823.
2005
Preclinical studies of the novel vascular disrupting agent MN-029.
Anticancer research. 25(6B):3899-904 [PMID] 16309177.
2005
Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck: a prospective, randomized trial.
Cancer. 104(2):332-7 [PMID] 15937906.
2005
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.
In vivo (Athens, Greece). 19(6):1045-50 [PMID] 16277020.
2005
The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.
International journal of radiation oncology, biology, physics. 62(3):846-53 [PMID] 15936569.
2004
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.
International journal of radiation oncology, biology, physics. 60(4):1233-40 [PMID] 15519796.
2004
Simultaneous targeting of VEGF message and VEGF receptor signaling as a therapeutic anticancer approach.
Anticancer research. 24(1):213-8 [PMID] 15015599.
2004
Targeting the tumor vasculature: a strategy to improve radiation therapy.
Expert review of anticancer therapy. 4(2):321-7 [PMID] 15056061.
2004
Therapeutic strategies that selectively target and disrupt established tumor vasculature.
Hematology/oncology clinics of North America. 18(5):1023-37, viii [PMID] 15474333.
2004
Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 73(3):359-66 [PMID] 15588883.
2004
Vascular-targeting therapies for treatment of malignant disease.
Cancer. 100(12):2491-9 [PMID] 15197790.
2003
Education and training for radiation scientists: radiation research program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12-14, 2003.
Radiation research. 160(6):729-37 [PMID] 14640790.
2003
Gene therapy delivery of endostatin enhances the treatment efficacy of radiation.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 66(1):1-9 [PMID] 12559515.
2003
Postoperative radiation therapy for squamous cell carcinoma of the head and neck.
American journal of otolaryngology. 24(1):41-50 [PMID] 12579482.
2003
Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy.
Seminars in radiation oncology. 13(1):53-61 [PMID] 12520464.
2002
Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi’s sarcoma.
Acta oncologica (Stockholm, Sweden). 41(1):98-105 [PMID] 11990526.
2002
Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo.
Cancer gene therapy. 9(6):513-21 [PMID] 12032662.
2002
Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126.
International journal of radiation oncology, biology, physics. 54(5):1512-7 [PMID] 12459379.
2002
Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus.
Anticancer research. 22(6A):3325-30 [PMID] 12530082.
2002
Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.
International journal of radiation oncology, biology, physics. 53(1):164-71 [PMID] 12007956.
2002
Enhancement of radiation therapy by vascular targeting agents.
Current opinion in investigational drugs (London, England : 2000). 3(11):1660-5 [PMID] 12476970.
2002
Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor.
British journal of cancer. 87(1):119-26 [PMID] 12085267.
2002
Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi’s sarcoma.
Acta oncologica (Stockholm, Sweden). 41(1):91-7 [PMID] 11990525.
2002
The 93rd Annual Meeting of the American Association for Cancer Research. 6-10 April 2002, San Francisco, California, USA.
Expert opinion on pharmacotherapy. 3(5):629-32 [PMID] 11996641.
2001
Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
Radiation research. 156(5 Pt 1):503-9 [PMID] 11604063.
2001
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 60(2):155-61 [PMID] 11439210.
2000
Altered fractionation in definitive irradiation of squamous cell carcinoma of the head and neck.
Current opinion in oncology. 12(3):207-14 [PMID] 10841192.
2000
Targeting tumor blood vessels: an adjuvant strategy for radiation therapy.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 57(1):5-12 [PMID] 11033183.
1999
Newly discovered anti-inflammatory properties of the benzamides and nicotinamides.
Molecular and cellular biochemistry. 193(1-2):119-25 [PMID] 10331648.
1998
Developing VDEPT for DT-diaphorase (NQO1) using an AAV vector plasmid.
International journal of radiation oncology, biology, physics. 42(4):909-12 [PMID] 9845120.
1998
Measurement of proliferation activities in human tumor models: a comparison of flow cytometric methods.
Radiation oncology investigations. 6(3):120-7 [PMID] 9652910.
1998
Potentiation of cisplatin activity by the bioreductive agent tirapazamine.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 47(2):215-20 [PMID] 9683372.
1998
Radiobiological hypoxia in the KHT sarcoma: predictions using the Eppendorf histograph.
International journal of radiation oncology, biology, physics. 40(5):1171-6 [PMID] 9539574.
1998
Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.
International journal of radiation oncology, biology, physics. 42(4):899-903 [PMID] 9845118.
1998
The tumor microenvironment: a double-edged sword.
International journal of radiation oncology, biology, physics. 42(4):697-9 [PMID] 9845079.
1997
Effects of ionizing radiation on the adhesive interaction of human tumor and endothelial cells in vitro.
Clinical & experimental metastasis. 15(1):12-8 [PMID] 9009101.
1997
Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 45(2):167-74 [PMID] 9424008.
1997
Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance.
International journal of radiation oncology, biology, physics. 39(4):789-95 [PMID] 9369124.
1996
Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.
International journal of cancer. 67(3):372-8 [PMID] 8707411.
1996
Does neck stage predict local control after irradiation for head and neck cancer?
Oncology (Williston Park, N.Y.). 10(3):381-4; discussion: 384 [PMID] 8820450.
1996
The in situ tumour response to combinations of cyclophosphamide and tirapazamine.
The British journal of cancer. Supplement. 27:S65-9 [PMID] 8763849.
1995
Are direct measures of tumor oxygenation reflective of changes in tumor radiosensitivity following oxygen manipulation?
Acta oncologica (Stockholm, Sweden). 34(3):307-11 [PMID] 7779414.
1995
Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 34(1):47-53 [PMID] 7792398.
1995
DNA damage in cyclophosphamide-resistant tumor cells: the role of glutathione.
Cancer research. 55(8):1691-5 [PMID] 7712476.
1995
Fused pyrazine mono-N-oxides as bioreductive drugs. III. Characterization of RB 90740 in vitro and in vivo.
Anti-cancer drugs. 6(2):259-69 [PMID] 7795274.
1995
Should direct measurements of tumor oxygenation relate to the radiobiological hypoxic fraction of a tumor?
International journal of radiation oncology, biology, physics. 33(2):365-73 [PMID] 7673024.
1994
In vitro cytotoxicity and chemosensitizing activity of the dual function nitroimidazole RB 6145.
International journal of radiation oncology, biology, physics. 29(2):301-6 [PMID] 8195023.
1994
Investigations of perfusion-limited hypoxia and oxygenation in the KHT sarcoma.
Advances in experimental medicine and biology. 361:627-34 [PMID] 7597992.
1994
Morphological correlates of fractionated radiation of the mouse lung: early and late effects.
International journal of radiation oncology, biology, physics. 29(4):789-804 [PMID] 8040026.
1994
Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing.
Acta oncologica (Stockholm, Sweden). 33(4):371-6 [PMID] 8018368.
1994
Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation.
International journal of radiation oncology, biology, physics. 29(3):439-42 [PMID] 8005796.
1994
The combination of nicotinamide and carbogen breathing to improve tumour oxygenation prior to radiation treatment.
Advances in experimental medicine and biology. 361:635-42 [PMID] 7597993.
1994
The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 31(2):117-22 [PMID] 8066190.
1994
Thiol-related mechanisms of resistance in a murine tumor model.
International journal of radiation oncology, biology, physics. 29(2):387-92 [PMID] 7910817.
1993
Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time.
British journal of cancer. 68(2):269-73 [PMID] 8347481.
1993
In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
British journal of cancer. 68(6):1071-9 [PMID] 8260357.
1992
Activity of etoposide (VP-16) and teniposide (VM-26) in exponential and plateau phase human tumor cell cultures.
Anti-cancer drugs. 3(3):245-52 [PMID] 1525405.
1992
Cytotoxicity of dual function nitrofurans in rodent and human tumor cells.
International journal of radiation oncology, biology, physics. 22(4):697-700 [PMID] 1544840.
1992
Effect of a hypoxic tumor cell cytotoxic disulfide on the membrane and DNA of tumor cells in culture.
Anti-cancer drugs. 3(6):651-8 [PMID] 1337706.
1992
Modulation of the cell cycle-dependent cytotoxicity of adriamycin and 4-hydroperoxycyclophosphamide by novobiocin, an inhibitor of mammalian topoisomerase II.
Cancer research. 52(13):3515-20 [PMID] 1319822.
1992
Potentiation of alkylating chemotherapy by dual function nitrofurans in multi-cell spheroids and solid tumors.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 24(4):239-45 [PMID] 1410579.
1992
Thiol manipulation as a means of overcoming drug resistance in a novel cyclophosphamide-induced resistant cell line.
International journal of radiation oncology, biology, physics. 22(4):781-4 [PMID] 1544852.
1992
Tissue oxygen manipulation and tumor blood flow.
International journal of radiation oncology, biology, physics. 22(3):393-5 [PMID] 1735667.
1991
Activity of etoposide (VP-16) in human tumor cells under different growth conditions.
International journal of radiation oncology, biology, physics. 20(2):373-5 [PMID] 1991703.
1991
Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy.
International journal of radiation oncology, biology, physics. 20(2):287-9 [PMID] 1991690.
1991
Interleukin 1 alpha stimulates hemopoiesis but not tumor cell proliferation and protects mice from lethal total body irradiation.
International journal of radiation oncology, biology, physics. 20(3):447-56 [PMID] 1995530.
1991
Prediction of tumour sensitivity to 4-hydroperoxycyclophosphamide by a glutathione-targeted assay.
British journal of cancer. 63(2):217-22 [PMID] 1997098.
1990
Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
British journal of cancer. 62(3):348-53 [PMID] 2206941.
1990
Evaluation of cell subpopulations isolated from human tumor xenografts by centrifugal elutriation.
International journal of radiation oncology, biology, physics. 18(5):1061-7 [PMID] 2347715.
1989
A study of the mechanism of resistance to Adriamycin in vivo. Glutathione metabolism, P-glycoprotein expression, and drug transport.
Biochemical pharmacology. 38(21):3697-705 [PMID] 2574574.
1989
Changes in cellular glutathione content during adriamycin treatment in human ovarian cancer–a possible indicator of chemosensitivity.
British journal of cancer. 60(3):291-8 [PMID] 2789934.
1989
Do in vitro studies of potential lethal damage repair predict for in situ results?
International journal of radiation biology. 56(5):567-71 [PMID] 2573648.
1989
Effect of thiol manipulation on chemopotentiation by nitroimidazoles.
International journal of radiation oncology, biology, physics. 16(5):1341-5 [PMID] 2715088.
1989
Heterogeneity of glutathione content in human ovarian cancer.
Cancer research. 49(19):5244-8 [PMID] 2766292.
1989
Isolation by flow cytometry of a human ovarian tumor cell subpopulation exhibiting a high glutathione content phenotype and increased resistance to adriamycin.
International journal of radiation oncology, biology, physics. 16(5):1315-9 [PMID] 2715085.
1989
Manipulations in the oxygen transport capacity of blood as a means of sensitizing tumors to radiation therapy.
International journal of radiation oncology, biology, physics. 16(5):1169-72 [PMID] 2715065.
1989
The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model.
International journal of radiation oncology, biology, physics. 16(4):1115-8 [PMID] 2703392.
1988
Applicability of animal tumor data to cancer therapy in humans.
International journal of radiation oncology, biology, physics. 14(5):913-27 [PMID] 3283086.
1988
Characterization of radiation resistant hypoxic cell subpopulations in KHT sarcomas. (II). Cell sorting.
British journal of cancer. 58(3):296-300 [PMID] 3179180.
1988
Comparison of glutathione levels in rodent and human tumor cells grown in vitro and in vivo.
Cancer research. 48(13):3657-60 [PMID] 3378208.
1988
Glutathione as a determinant of cellular response to doxorubicin.
NCI monographs : a publication of the National Cancer Institute. (6):211-5 [PMID] 3352767.
1988
Glutathione contents in human and rodent tumor cells in various phases of the cell cycle.
Cancer research. 48(13):3661-5 [PMID] 3378209.
1988
Modification of cyclophosphamide-induced pulmonary toxicity in normal mice.
NCI monographs : a publication of the National Cancer Institute. (6):51-3 [PMID] 3127733.
1988
Potentiation of combination chemotherapy by nitroheterocyclics.
International journal of radiation oncology, biology, physics. 15(1):129-34 [PMID] 3391809.
1988
Responses of tumor cell subpopulations to single modality and combined modality therapies.
NCI monographs : a publication of the National Cancer Institute. (6):101-5 [PMID] 3127731.
1987
A human colon adenocarcinoma xenograft–radiation response, cellular composition, and tumor disaggregation.
Journal of the National Cancer Institute. 78(2):371-6 [PMID] 3468298.
1987
Characterization of radiation resistant hypoxic cell subpopulations in KHT sarcomas. (I). Centrifugal elutriation.
British journal of cancer. 55(1):33-6 [PMID] 3814473.
1987
Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine.
British journal of cancer. 56(1):33-8 [PMID] 3620316.
1987
Evaluation of CCNU and misonidazole in the treatment of advanced colorectal cancer.
American journal of clinical oncology. 10(3):213-5 [PMID] 3591741.
1987
Potentiation of CCNU activity by misonidazole in metastases.
Clinical & experimental metastasis. 5(1):57-63 [PMID] 3829497.
1986
A semiquantitative probe for radiation-induced normal tissue damage at the molecular level.
Radiation research. 105(1):76-83 [PMID] 3511495.
1986
Cell cycle specific toxicity of the Hoechst 33342 stain in untreated or irradiated murine tumor cells.
Cancer research. 46(7):3556-9 [PMID] 3708586.
1986
Combinations of CCNU, MISO, and fractionated radiotherapy.
International journal of radiation oncology, biology, physics. 12(8):1379-82 [PMID] 3759559.
1986
Cyclophosphamide-induced pulmonary toxicity.
The British journal of cancer. Supplement. 7:343-6 [PMID] 3459536.
1986
Increased therapeutic benefit through the addition of misonidazole to a nitrosourea-radiation combination.
Cancer research. 46(2):629-32 [PMID] 3940631.
1986
Long term effects of radiation and combined modalities on mouse lung.
Scanning electron microscopy. (Pt 1):221-8 [PMID] 2426758.
1986
Predictive biochemical assays for late radiation effects.
International journal of radiation oncology, biology, physics. 12(4):469-76 [PMID] 3009366.
1986
Recovery of cell subpopulations from human tumour xenografts following dissociation with different enzymes.
British journal of cancer. 54(4):615-22 [PMID] 3535863.
1986
Sensitization of cancer chemotherapeutic agents by nitroheterocyclics.
Biochemical pharmacology. 35(1):111-5 [PMID] 3940521.
1986
Tumor radiosensitization through reductions in hemoglobin affinity.
International journal of radiation oncology, biology, physics. 12(8):1295-7 [PMID] 3759550.
1985
Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU 1069.
Cancer treatment reports. 69(12):1409-14 [PMID] 3841024.
1985
In vivo interaction between radiation and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the absence or presence of misonidazole in mice.
Cancer research. 45(1):198-202 [PMID] 3965132.
1984
Characterization of growth and radiation response of KHT tumor cells metastatic from lung to ovary and kidney.
Clinical & experimental metastasis. 2(1):73-81 [PMID] 6543692.
1984
Chemopotentiation in vivo: no loss of sensitization with fractionation.
British journal of cancer. 50(4):509-17 [PMID] 6487517.
1984
Comparison of tumour age response to radiation for cells derived from tissue culture or solid tumours.
British journal of cancer. 50(4):519-26 [PMID] 6487518.
1984
Enhanced tumor responses through therapies combining CCNU, MISO and radiation.
International journal of radiation oncology, biology, physics. 10(9):1623-6 [PMID] 6480451.
1984
Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole.
British journal of cancer. 49(6):787-93 [PMID] 6733024.
1984
In situ radiation response and oxygen enhancement ratio of KHT sarcoma cells in various phases of the cell cycle.
The British journal of radiology. 57(682):823-7 [PMID] 6478140.
1984
In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole.
British journal of cancer. 49(6):795-9 [PMID] 6733025.
1984
Modification of chemotherapy by nitroimidazoles.
International journal of radiation oncology, biology, physics. 10(9):1585-94 [PMID] 6384159.
1984
Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
International journal of radiation oncology, biology, physics. 10(9):1657-60 [PMID] 6548212.
1984
Radiation induced secretion of surfactant from cell cultures of type II pneumocytes: an in vitro model of radiation toxicity.
International journal of radiation oncology, biology, physics. 10(3):375-8 [PMID] 6546743.
1984
Survival in subpopulations of cells derived from solid KHT sarcomas by centrifugal elutriation following treatment with CCNU and MISO.
International journal of radiation oncology, biology, physics. 10(9):1615-8 [PMID] 6480449.
1984
The effect in the KHT sarcoma of CCNU and MISO on cell cycle progression evaluated by flow-cytometry.
International journal of radiation oncology, biology, physics. 10(9):1619-22 [PMID] 6480450.
1983
Effect of pretreatment with phenobarbital or SKF 525A on the toxicity and antitumor activity of lomustine.
Cancer treatment reports. 67(3):259-65 [PMID] 6831472.
1983
In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines.
Cancer research. 43(10):4709-13 [PMID] 6883329.
1983
In vivo potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea by the radiation sensitizer benznidazole.
Cancer research. 43(3):1010-3 [PMID] 6825075.
1983
Quantitative changes in the arterial blood gases of mice following localized irradiation of the lungs.
Radiation research. 93(3):560-6 [PMID] 6407058.
1983
Surfactant release as an early measure of radiation pneumonitis.
International journal of radiation oncology, biology, physics. 9(11):1669-73 [PMID] 6689007.
1982
Cell survival recovery kinetics in the KHT sarcoma following treatment with five alkylating agents and misonidazole.
International journal of radiation oncology, biology, physics. 8(3-4):619-22 [PMID] 7107384.
1982
Combinations of cyclophosphamide and misonidazole in the KHT sarcoma.
International journal of radiation oncology, biology, physics. 8(3-4):647-50 [PMID] 7107391.
1982
Early and late pulmonary toxicity in mice evaluated 180 and 420 days following localized lung irradiation.
Radiation research. 89(2):396-407 [PMID] 7063621.
1982
Morphologic changes reflecting early and late effects of irradiation of the distal lung of the mouse: a review.
Scanning electron microscopy. (Pt 1):413-25 [PMID] 7167757.
1982
Nitrosourea-misonidazole combination chemotherapy: effect on KHT sarcomas, marrow stem cells and gut.
British journal of cancer. 45(6):835-42 [PMID] 6212075.
1982
Potentiation of chemotherapy by hypoxic cell radiation sensitizers–a review.
International journal of radiation oncology, biology, physics. 8(6):1029-34 [PMID] 7050050.
1982
Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
British journal of cancer. 45(2):272-81 [PMID] 6460517.
1982
Sequential effects of irradiation on the pulmonary surfactant system.
International journal of radiation oncology, biology, physics. 8(5):879-82 [PMID] 6896708.
1982
The response of mouse lung tumors to combinations of CCNU and misonidazole.
International journal of radiation oncology, biology, physics. 8(3-4):627-30 [PMID] 7107386.
1981
Cell subpopulations dispersed from solid tumours and separated by centrifugal elutriation.
British journal of cancer. 44(1):100-8 [PMID] 7259956.
1981
Combinations of radiation and misonidazole in a murine lung tumor model.
Radiation research. 86(2):387-97 [PMID] 7232698.
1981
Direct synchronization of cells from solid tumors by centrifugal elutriation.
Experimental cell research. 134(1):15-22 [PMID] 7250214.
1981
Effects of radiation on the mouse lung and potential induction of radiation pneumonitis.
Virchows Archiv. B, Cell pathology including molecular pathology. 37(3):327-36 [PMID] 6117977.
1981
In vivo combination of misonidazole and the chemotherapeutic agent CCNU.
British journal of cancer. 43(3):367-77 [PMID] 7225287.
1981
In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.
British journal of cancer. 43(1):93-9 [PMID] 7459244.
1980
Analysis of blood gas values in mice following pulmonary irradiation.
Radiation research. 81(2):303-10 [PMID] 7360887.
1980
In vivo tumor response to single and multiple exposures of adriamycin.
European journal of cancer. 16(11):1433-40 [PMID] 7227420.
1980
The interaction between adriamycin and radiation in a solid murine tumor.
Radiation research. 83(2):345-59 [PMID] 7403440.
1980
Tumour size: a factor influencing the isoeffect analysis of tumour response to combined modalities.
The British journal of cancer. Supplement. 4:294-8 [PMID] 6932939.
1979
A comparison of the pharmacokinetics of multiple and single dose administrations of adriamycin.
International journal of radiation oncology, biology, physics. 5(8):1271-4 [PMID] 528276.
1979
Animal age: a factor influencing the time of death following local thoracic irradiation.
International journal of radiation oncology, biology, physics. 5(11-12):2069-72 [PMID] 544588.
1979
The in vivo radiation response of an experimental tumor: the effect of exposing tumor-bearing mice to a reduced oxygen environment prior to but not during irradiation.
International journal of radiation oncology, biology, physics. 5(1):61-8 [PMID] 422416.
1978
Smoking: the influence of carboxyhemoglobin (HbCO) on tumor oxygenation and response to radiation.
International journal of radiation oncology, biology, physics. 4(7-8):657-62 [PMID] 711537.
1978
The effect of chronic reductions in the arterial partial pressure of oxygen on the radiation response of an experimental tumour.
The British journal of radiology. 51(612):992-6 [PMID] 737413.
1977
The importance of the pre-irradiation breathing times of oxygen and carbogen (5% CO2: 95% O2) on the in vivo radiation response of a murine sarcoma.
International journal of radiation oncology, biology, physics. 2(9-10):903-11 [PMID] 591407.
1975
The relationship between mouse arterial partial pressure of oxygen (PaO2) and the effectiveness of localized tumour irradiation.
The British journal of radiology. 48(572):662-7 [PMID] 1182421.

Grants

Jul 2024 ACTIVE
CRAVE – Cancer Research Administration Virtual Experience
Role: Co-Project Director/Principal Investigator
Funding: Natl Cncl of Univ Res Administrators
Jun 2023 ACTIVE
UF Health Cancer Center Support Grant
Role: Other
Funding: NATL INST OF HLTH NCI
Apr 2021 ACTIVE
Team-based Interdisciplinary Cancer Research Training Program
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Jun 2020 – May 2023
Lipidnanoparticle vaccines targeting metastatic lung cancer from osteosarcoma
Role: Co-Project Director/Principal Investigator
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Aug 2018 – May 2022
Pglyrp3 cooperates with Snail1 to mediate anti-tumor immune response in breast cancer
Role: Other
Funding: NATL INST OF HLTH NCI
Jun 2016 – May 2022
Hypoxia: Impact on Src Signaling and Prostate CancerMetastasis
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Dec 2015 – Dec 2018
RESEARCH IN RADIOBIOLOGY
Role: Principal Investigator
Funding: UF FOUNDATION
Feb 2015 – Oct 2023
UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Feb 2015 – Jan 2020
UF Health Cancer Center Collaborative Cancer Related Seed Grant funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Jan 2015 – May 2024
UF Health Cancer Center Bridge Seed Grant funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Jan 2015 – Dec 2018
3Modulation of Tumor Oxygenation to Enhance Radiotherapy
Role: Principal Investigator
Funding: KANSAS STATE UNIVERSITY via AMERICAN CANCER SOCIETY
Sep 2014 – Aug 2019
Florida Minority Cancer Research and Training Center: Feasibility Studies
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Jun 2014 – May 2016
Testing the In Vivo Potential of Magnetically Mediated Energy Delivery to treat Metastatic Breast Cancer
Role: Project Manager
Funding: UF DSR OPPORTUNITY FUND
Jul 2013 – Apr 2019
Targeting Cathepsin L: A Novel Strategy to Impede Prostate and Breast Cancer Metastasis
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
May 2012 – Apr 2017
Metastasis Program (Breast and Prostate)
Role: Principal Investigator
Funding: FL CLINICAL PRACTICE ASSO
Dec 2006 – Mar 2018
UFSCC Endowment to support cancer center research
Role: Project Manager
Funding: UF FOUNDATION
Jul 2006 – Dec 2020
21st Century Research & Economic Development Investment Program (REDIP)
Role: Project Manager
Funding: STATE UNIV SYS OF FL BOARD OF GOVERNORS

Contact Details

Phones:
Business:
(352) 265-0287
Emails:
Business:
siemadw@ufl.edu
Addresses:
Business Mailing:
PO Box 100385
GAINESVILLE FL 32610
Business Street:
1376 MOWREY ROAD
ROOM 457
CANCER/GENETICS COMPLEX
GAINESVILLE FL 32611